Liver Diseases  >>  furaprevir (TG-2349)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
furaprevir (TG-2349) / TaiGen
NCT01523990: A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients

Completed
1
135
US
TG-2349, placebo
TaiGen Biotechnology Co., Ltd.
Healthy, Hepatitis C, Chronic
04/12
07/13

Download Options